CN1097006A - O-芳基吗啡喃的醚类化合物 - Google Patents

O-芳基吗啡喃的醚类化合物 Download PDF

Info

Publication number
CN1097006A
CN1097006A CN94100181A CN94100181A CN1097006A CN 1097006 A CN1097006 A CN 1097006A CN 94100181 A CN94100181 A CN 94100181A CN 94100181 A CN94100181 A CN 94100181A CN 1097006 A CN1097006 A CN 1097006A
Authority
CN
China
Prior art keywords
morphinan
formula
methyl
pyridyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN94100181A
Other languages
English (en)
Chinese (zh)
Inventor
E·莫哈西
J·P·奥布赖恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN1097006A publication Critical patent/CN1097006A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/28—Morphinans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN94100181A 1993-01-06 1994-01-05 O-芳基吗啡喃的醚类化合物 Pending CN1097006A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US113593A 1993-01-06 1993-01-06
US001,135 1993-01-06

Publications (1)

Publication Number Publication Date
CN1097006A true CN1097006A (zh) 1995-01-04

Family

ID=21694554

Family Applications (1)

Application Number Title Priority Date Filing Date
CN94100181A Pending CN1097006A (zh) 1993-01-06 1994-01-05 O-芳基吗啡喃的醚类化合物

Country Status (23)

Country Link
EP (1) EP0612730B1 (enExample)
JP (1) JP2501298B2 (enExample)
KR (1) KR940018094A (enExample)
CN (1) CN1097006A (enExample)
AT (1) ATE154931T1 (enExample)
AU (1) AU681601B2 (enExample)
BR (1) BR9400021A (enExample)
CA (1) CA2110337A1 (enExample)
CZ (1) CZ2294A3 (enExample)
DE (1) DE69311887T2 (enExample)
DK (1) DK0612730T3 (enExample)
ES (1) ES2105061T3 (enExample)
FI (1) FI940041L (enExample)
GR (1) GR3024891T3 (enExample)
HU (2) HUT66061A (enExample)
IL (1) IL108247A (enExample)
MX (1) MX9400177A (enExample)
NO (1) NO940028D0 (enExample)
NZ (1) NZ250580A (enExample)
PL (1) PL175365B1 (enExample)
TW (1) TW264473B (enExample)
UY (1) UY23706A1 (enExample)
ZA (1) ZA939806B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1105560C (zh) * 1996-08-12 2003-04-16 皮埃尔法博赫药品公司 依法克生用于制备治疗亨廷顿舞蹈病的药物的应用
CN100368414C (zh) * 2002-07-03 2008-02-13 阿尔卡森制药有限公司 吗啡喃衍生物及其14位取代季铵盐、制备方法和它们的用途
CN103044327A (zh) * 2013-01-07 2013-04-17 苏州立新制药有限公司 一种右美沙芬的制备方法

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9522176D0 (en) * 1995-10-30 1996-01-03 Iaf Biochem Int Morphinan derivatives having neuroprotective activity
EP1384720A1 (en) * 1996-06-13 2004-01-28 SUMIKA FINE CHEMICALS Co., Ltd. Process for drying paroxetine hydrochloride
GB9706753D0 (en) * 1997-04-03 1997-05-21 Pharmacia & Upjohn Spa Aralkoxy-morphinan derivatives
KR100425881B1 (ko) * 2001-03-14 2004-04-03 고광호 신규한 몰피난 유도체
WO2003097608A2 (en) * 2002-05-17 2003-11-27 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US20040204862A1 (en) * 2003-04-11 2004-10-14 Wainer Irving W. Computer-based model for identification and characterization for non-competitive inhibitors of nicotinic acetylcholine receptors and related ligand-gated ion channel receptors
US8017622B2 (en) 2003-05-16 2011-09-13 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
JP5784507B2 (ja) * 2009-02-23 2015-09-24 マリンクロッド エルエルシー （＋）−モルフィナニウム第四級塩およびその生成方法
US20190111047A1 (en) * 2014-09-14 2019-04-18 Avanir Pharmaceuticals, Inc. Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
US20160243112A1 (en) * 2015-02-25 2016-08-25 Alkermes, Inc. Treatments for alzheimer's related diseases and disorders
EP4206203A4 (en) * 2020-08-28 2024-12-11 Nippon Chemiphar Co., Ltd. PROCESS FOR PREPARING A MORPHINAN DERIVATIVE WITH A MAIN CHAIN FORMED FROM DIARYL ETHER USING A NOVEL COPPER CATALYST

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI773636A7 (fi) * 1976-12-06 1978-06-07 Hoffmann La Roche Nya fenylderivat
US4113729A (en) * 1976-12-06 1978-09-12 Hoffmann-La Roche Inc. 3-Phenoxymorphinans and derivatives thereof
US4806543A (en) * 1986-11-25 1989-02-21 Board Of Trustees Of The Leland Stanford Junior University Method and compositions for reducing neurotoxic injury

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1105560C (zh) * 1996-08-12 2003-04-16 皮埃尔法博赫药品公司 依法克生用于制备治疗亨廷顿舞蹈病的药物的应用
CN100368414C (zh) * 2002-07-03 2008-02-13 阿尔卡森制药有限公司 吗啡喃衍生物及其14位取代季铵盐、制备方法和它们的用途
CN103044327A (zh) * 2013-01-07 2013-04-17 苏州立新制药有限公司 一种右美沙芬的制备方法
CN103044327B (zh) * 2013-01-07 2014-12-17 苏州立新制药有限公司 一种右美沙芬的制备方法

Also Published As

Publication number Publication date
IL108247A (en) 1998-02-22
HU211290A9 (en) 1995-11-28
UY23706A1 (es) 1994-06-05
ES2105061T3 (es) 1997-10-16
NO940028D0 (no) 1994-01-04
GR3024891T3 (en) 1998-01-30
PL301784A1 (en) 1994-07-11
PL175365B1 (pl) 1998-12-31
AU681601B2 (en) 1997-09-04
HU9400002D0 (en) 1994-05-30
MX9400177A (es) 1994-07-29
EP0612730A1 (en) 1994-08-31
TW264473B (enExample) 1995-12-01
DE69311887D1 (de) 1997-08-07
ZA939806B (en) 1994-07-06
BR9400021A (pt) 1994-07-26
JP2501298B2 (ja) 1996-05-29
FI940041A0 (fi) 1994-01-05
DE69311887T2 (de) 1998-01-15
JPH06316564A (ja) 1994-11-15
HUT66061A (en) 1994-09-28
KR940018094A (ko) 1994-08-16
FI940041A7 (fi) 1994-07-07
FI940041L (fi) 1994-07-07
AU5280793A (en) 1994-07-14
CZ2294A3 (en) 1994-07-13
CA2110337A1 (en) 1994-07-07
DK0612730T3 (da) 1998-02-02
ATE154931T1 (de) 1997-07-15
NO940028L (enExample) 1994-07-07
EP0612730B1 (en) 1997-07-02
IL108247A0 (en) 1994-04-12
NZ250580A (en) 1996-07-26

Similar Documents

Publication Publication Date Title
CN1273451C (zh) 哌啶mch拮抗剂及其治疗肥胖症的用途
CN1028103C (zh) 哌啶基苯并咪唑类化合物的制备方法
CN1092643C (zh) 用于增强记忆的氨甲基苯基咪唑衍生物
CN1044816A (zh) 关于有机化合物的改进
CN1708481A (zh) 作为抗微生物剂的n－烷基－4－亚甲基氨基－3－羟基－2－吡啶酮
CN1649845A (zh) 蝇蕈碱拮抗剂
CN1142226A (zh) 新的杂环化合物
CN1097006A (zh) O-芳基吗啡喃的醚类化合物
CN1111245A (zh) 雪花胺衍生物、其制备方法及其作为药物的用途
CN1117965A (zh) 取代的4-苯基-吡啶酮和4-苯基-2-烷氧基吡啶
CN1832945A (zh) 二苯基吡啶衍生物,其制备及治疗用途
CN1264378A (zh) 作为nk－2和nk－3受体拮抗剂的喹啉－4－甲酰胺衍生物
CN1040440C (zh) 去氢环黄皮酰胺衍生物的制备方法
CN86107695A (zh) 不同的氮-取代的3-哌啶羧酸或氮-取代的3-吡啶羧酸及它们的衍生物
CN88100986A (zh) 芳香基哌嗪基-亚烷基苯基-杂环化合物
CN1041088C (zh) 光学活性咪唑烷酮衍生物和抗痴呆药物组合物
CN1956962A (zh) 四氢异喹啉磺酰胺衍生物，其制备方法及其在治疗中的应用
CN1461301A (zh) 苯并[b]噻吩衍生物及其制备方法
CN1064075A (zh) 氨基甲酸衍生物及其制备方法
CN1027066C (zh) 吲哚衍生物的制备方法
CN1090629C (zh) 新的杂环化合物
CN1195739C (zh) 2－氨磺酰苯甲酸衍生物
CN1055472C (zh) 噁唑并喹啉酮衍生物,它们的制备及其在治疗上的应用
CN1087337A (zh) 取代的喹啉-2-基甲氧基苯乙酸衍生物
CN1875018A (zh) 制备噻唑烷二酮的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned
C20 Patent right or utility model deemed to be abandoned or is abandoned